nach oben

Journal of Thrombosis and Thrombolysis

Erschienen in:

27.04.2019

Contradictory to its effects on thrombin, C1-inhibitor reduces plasmin generation in the presence of thrombomodulin

verfasst von: Ivan D. Tarandovskiy, Ali A. Rajabi, Elena Karnaukhova, Paul W. Buehler

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

C1-inhibitor (C1INH) was shown to enhance thrombin generation (TG) in the presence of thrombomodulin (TM) by reducing production of activated protein C. Because C1INH is known to inhibit fibrinolytic system proteases, the objective of this study was to evaluate the effect of moderate (3 IU/ml) and high (16 IU/ml) C1INH concentrations on TG and plasmin generation (PG) in the presence of TM. These concentrations were evaluated based on expected maximum plasma levels following C1INH replacement therapy and recently suggested supraphysiologic dosing. TG and PG were investigated in platelet poor plasmas obtained from 21 healthy donors. An assay designed to monitor the continuous generation of the 7-amino-4-methylcoumarin fluorescence from substrates specific to thrombin or plasmin was used to evaluate the impact of C1INH activity. To characterize the C1INH effects on TG and PG, the thrombin and plasmin concentration peaks and production rates were calculated. TM addition to donor plasma shifted the concentration dependence of C1INH on TG parameters from reduction to enhancement. Conversely, PG parameters were significantly reduced by 16 IU/ml in both the presence and absence of TM. Moderate C1INH concentration (3 IU/ml) reduced TG and PG in the absence of TM but did not significantly affect these parameters in the presence of TM. Finally, 3 IU/ml of C1INH reduced PG more so than TG in the absence of TM. The presented results suggest a mechanism by which C1INH could potentiate thrombosis by inhibition of fibrinolysis.

Nur mit Berechtigung zugänglich

Tarandovskiy ID, Buehler PW, Ataullakhanov FI, Karnaukhova E (2019) C1-esterase inhibitor enhances thrombin generation and spatial fibrin clot propagation in the presence of thrombomodulin. Thromb Res 176:54–60. https://doi.org/10.1016/j.thromres.2019.02.013 CrossRefPubMed

Karnaukhova E (2013) C1-esterase inhibitor: biological activities and therapeutic applications. J Hematol Thromboembol Dis 1(3):1–7

Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE (2000) C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 52(1):91–112PubMed

Davis AE 3rd (2005) The pathophysiology of hereditary angioedema. Clin Immunol 114(1):3–9. https://doi.org/10.1016/j.clim.2004.05.007 CrossRefPubMed

Cugno M, Bos I, Lubbers Y, Hack CE, Agostoni A (2001) In vitro interaction of C1-inhibitor with thrombin. Blood Coagul Fibrinolysis 12(4):253–260PubMed

Brown EW, Ravindran S, Patston PA (2002) The reaction between plasmin and C1-inhibitor results in plasmin inhibition by the serpin mechanism. Blood Coagul Fibrinolysis 13(8):711–714PubMed

Caccia S, Castelli R, Maiocchi D, Bergamaschini L, Cugno M (2011) Interaction of C1 inhibitor with thrombin on the endothelial surface. Blood Coagul Fibrinolysis 22(7):571–575. https://doi.org/10.1097/MBC.0b013e3283494ba7 CrossRefPubMed

Schoenfeld AK, Lahrsen E, Alban S (2016) Regulation of complement and contact system activation via C1 inhibitor potentiation and factor XIIa activity modulation by sulfated glycans: structure-activity relationships. PLoS ONE 11(10):e0165493. https://doi.org/10.1371/journal.pone.0165493 CrossRefPubMedPubMedCentral

Wuillemin WA, Minnema M, Meijers JC, Roem D, Eerenberg AJ, Nuijens JH, ten Cate H, Hack CE (1995) Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood 85(6):1517–1526PubMed

10.

Nuijens JH, Eerenberg-Belmer AJ, Huijbregts CC, Schreuder WO, Felt-Bersma RJ, Abbink JJ, Thijs LG, Hack CE (1989) Proteolytic inactivation of plasma C1-inhibitor in sepsis. J Clin Invest 84(2):443–450. https://doi.org/10.1172/JCI114185 CrossRefPubMedPubMedCentral

11.

Whicher JT, Barnes MP, Brown A, Cooper MJ, Read R, Walters G, Williamson RC (1982) Complement activation and complement control proteins in acute pancreatitis. Gut 23(11):944–950PubMedPubMedCentral

12.

Caccia S, Suffritti C, Cicardi M (2014) Pathophysiology of hereditary angioedema. Pediatr Allergy Immunol Pulmonol 27(4):159–163. https://doi.org/10.1089/ped.2014.0425 CrossRefPubMedPubMedCentral

13.

Shire ViroPharma. CINRYZE (C1 Esterase Inhibitor [Human]) prescribing information. http://pi.shirecontent.com/PI/PDFs/Cinryze_USA_ENG.pdf. Updated September 2014. Accessed Feb 19, 2018

14.

CSL Behring. Haegarda (C1-esterase inhibitor [human]) prescribing information. http://labeling.cslbehring.com/PRODUCT-DOCUMENT/US/HAEGARDA/EN/HAEGARDA-Referral-Form.pdf. Accessed May 24, 2018

15.

CSL Behring. Berinert (C1-esterase inhibitor [human]) prescribing information. http://labeling.cslbehring.com/PI/US/Berinert/EN/Berinert-Prescribing-Information.pdf. Accessed Feb 19, 2018

16.

Rathbun KM (2019) Angioedema after thrombolysis with tissue plasminogen activator: an airway emergency. Oxf Med Case Rep 2019(1):omy112. https://doi.org/10.1093/omcr/omy112 CrossRef

17.

Panagiotou A, Trendelenburg M, Osthoff M (2018) The lectin pathway of complement in myocardial ischemia/reperfusion injury-review of its significance and the potential impact of therapeutic interference by C1 esterase inhibitor. Front Immunol 9:1151. https://doi.org/10.3389/fimmu.2018.01151 CrossRefPubMedPubMedCentral

18.

Castellano G, Franzin R, Stasi A, Divella C, Sallustio F, Pontrelli P, Lucarelli G, Battaglia M, Staffieri F, Crovace A, Stallone G, Seelen M, Daha MR, Grandaliano G, Gesualdo L (2018) Complement activation during ischemia/reperfusion injury induces pericyte-to-myofibroblast transdifferentiation regulating peritubular capillary lumen reduction through pERK signaling. Front Immunol 9:1002. https://doi.org/10.3389/fimmu.2018.01002 CrossRefPubMedPubMedCentral

19.

Berger M, Baldwin WM 3rd, Jordan SC (2016) Potential roles for C1 inhibitor in transplantation. Transplantation 100(7):1415–1424. https://doi.org/10.1097/TP.0000000000000995 CrossRefPubMed

20.

Saidi RF, Rajeshkumar B, Shariftabrizi A, Dresser K, Walter O (2014) Human C1 inhibitor attenuates liver ischemia-reperfusion injury and promotes liver regeneration. J Surg Res 187(2):660–666. https://doi.org/10.1016/j.jss.2013.09.009 CrossRefPubMed

21.

Tradtrantip L, Asavapanumas N, Phuan PW, Verkman AS (2014) Potential therapeutic benefit of C1-esterase inhibitor in neuromyelitis optica evaluated in vitro and in an experimental rat model. PLoS ONE 9(9):e106824. https://doi.org/10.1371/journal.pone.0106824 CrossRefPubMedPubMedCentral

22.

Committee GMPsD, Severe thrombus formation of Berinert IHS (2000). Deutsches Arzteblatt

23.

Gandhi PK, Gentry WM, Bottorff MB (2012) Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy 32(10):902–909. https://doi.org/10.1002/j.1875-9114.2012.01126 CrossRefPubMed

24.

Crowther M, Bauer KA, Kaplan AP (2014) The thrombogenicity of C1 esterase inhibitor (human): review of the evidence. Allergy Asthma Proc 35(6):444–453. https://doi.org/10.2500/aap.2014.35.3799 CrossRefPubMed

25.

Schurmann D, Herzog E, Raquet E, Nolte MW, May F, Muller-Cohrs J, Bjorkqvist J, Dickneite G, Pragst I (2014) C1-esterase inhibitor treatment: preclinical safety aspects on the potential prothrombotic risk. Thromb Haemost 112(5):960–971. https://doi.org/10.1160/TH13-06-0469 CrossRefPubMedPubMedCentral

26.

Horstick G, Berg O, Heimann A, Gotze O, Loos M, Hafner G, Bierbach B, Petersen S, Bhakdi S, Darius H, Horstick M, Meyer J, Kempski O (2001) Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation 104(25):3125–3131PubMed

27.

Levy JH, Szlam F, Gelone S (2014) Effects of a plasma-derived C1 esterase inhibitor on hemostatic activation, clot formation, and thrombin generation. Blood Coagul Fibrinolysis 25(8):883–889. https://doi.org/10.1097/MBC.0000000000000178 CrossRefPubMed

28.

Landsem A, Fure H, Mollnes TE, Nielsen EW, Brekke OL (2016) C1-inhibitor efficiently delays clot development in normal human whole blood and inhibits Escherichia coli-induced coagulation measured by thromboelastometry. Thromb Res 143:63–70. https://doi.org/10.1016/j.thromres.2016.04.024 CrossRefPubMed

29.

van Geffen M, Cugno M, Lap P, Loof A, Cicardi M, van Heerde W (2012) Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency. Clin Exp Immunol 167(3):472–478. https://doi.org/10.1111/j.1365-2249.2011.04541.x CrossRefPubMedPubMedCentral

30.

Baerga-Ortiz A, Rezaie AR, Komives EA (2000) Electrostatic dependence of the thrombin-thrombomodulin interaction. J Mol Biol 296(2):651–658. https://doi.org/10.1006/jmbi.1999.3447 CrossRefPubMed

31.

Yang L, Manithody C, Rezaie AR (2006) Activation of protein C by the thrombin-thrombomodulin complex: cooperative roles of Arg-35 of thrombin and Arg-67 of protein C. Proc Natl Acad Sci USA 103(4):879–884. https://doi.org/10.1073/pnas.0507700103 CrossRefPubMed

32.

Panteleev MA, Ovanesov MV, Kireev DA, Shibeko AM, Sinauridze EI, Ananyeva NM, Butylin AA, Saenko EL, Ataullakhanov FI (2006) Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively. Biophys J 90(5):1489–1500. https://doi.org/10.1529/biophysj.105.069062 CrossRefPubMed

33.

Wang W, Nagashima M, Schneider M, Morser J, Nesheim M (2000) Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation. J Biol Chem 275(30):22942–22947. https://doi.org/10.1074/jbc.M001760200 CrossRefPubMed

34.

Anastasiou G, Gialeraki A, Merkouri E, Politou M, Travlou A (2012) Thrombomodulin as a regulator of the anticoagulant pathway: implication in the development of thrombosis. Blood Coagul Fibrinolysis 23(1):1–10. https://doi.org/10.1097/MBC.0b013e32834cb271 CrossRefPubMed

35.

Boehme MW, Deng Y, Raeth U, Bierhaus A, Ziegler R, Stremmel W, Nawroth PP (1996) Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies. Immunology 87(1):134–140PubMedPubMedCentral

36.

Lohi O, Urban S, Freeman M (2004) Diverse substrate recognition mechanisms for rhomboids; thrombomodulin is cleaved by mammalian rhomboids. Curr Biol 14(3):236–241. https://doi.org/10.1016/j.cub.2004.01.025 CrossRefPubMed

37.

Furugohri T, Sugiyama N, Morishima Y, Shibano T (2011) Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system. Thromb Haemost 106(6):1076–1083. https://doi.org/10.1160/TH11-06-0382 CrossRefPubMed

38.

Perzborn E, Heitmeier S, Buetehorn U, Laux V (2014) Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo. J Thromb Haemost 12(7):1054–1065. https://doi.org/10.1111/jth.12591 CrossRefPubMedPubMedCentral

39.

Dashkevich NM, Ovanesov MV, Balandina AN, Karamzin SS, Shestakov PI, Soshitova NP, Tokarev AA, Panteleev MA, Ataullakhanov FI (2012) Thrombin activity propagates in space during blood coagulation as an excitation wave. Biophys J 103(10):2233–2240. https://doi.org/10.1016/j.bpj.2012.10.011 CrossRefPubMedPubMedCentral

40.

Hemker HC, Al Dieri R, De Smedt E, Beguin S (2006) Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 96(5):553–561PubMed

41.

Tarandovskiy ID, Artemenko EO, Panteleev MA, Sinauridze EI, Ataullakhanov FI (2013) Antiplatelet agents can promote two-peaked thrombin generation in platelet rich plasma: mechanism and possible applications. PLoS ONE 8(2):e55688. https://doi.org/10.1371/journal.pone.0055688 CrossRefPubMedPubMedCentral

42.

Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, Krymskaya OV, Ataullakhanov FI (2007) Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 97(3):425–434PubMed

43.

Gracheva MA, Urnova ES, Sinauridze EI, Tarandovskiy ID, Orel EB, Poletaev AV, Mendeleeva LP, Ataullakhanov FI, Balandina AN (2015) Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma. Leuk Lymphoma 56(12):3418–3425. https://doi.org/10.3109/10428194.2015.1041385 CrossRefPubMed

44.

Tarandovskiy ID, Balandina AN, Kopylov KG, Konyashina NI, Kumskova MA, Panteleev MA, Ataullakhanov FI (2013) Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics. Thromb Res 131(6):e274–280. https://doi.org/10.1016/j.thromres.2013.04.004 CrossRefPubMed

45.

Kamisato C, Furugohri T, Morishima Y (2016) A direct thrombin inhibitor suppresses protein C activation and factor Va degradation in human plasma: possible mechanisms of paradoxical enhancement of thrombin generation. Thromb Res 141:77–83. https://doi.org/10.1016/j.thromres.2016.03.005 CrossRefPubMed

46.

Matsumoto T, Nogami K, Shima M (2013) Simultaneous measurement of thrombin and plasmin generation to assess the interplay between coagulation and fibrinolysis. Thromb Haemost 110(4):761–768. https://doi.org/10.1160/TH13-04-0345 CrossRefPubMed

47.

Chang GMT, Atkinson HM, Berry LR, Chan AKC (2017) Inhibition of plasmin generation in plasma by heparin, low molecular weight heparin, and a covalent antithrombin-heparin complex. Blood Coagul Fibrinolysis 28(6):431–437. https://doi.org/10.1097/MBC.0000000000000611 CrossRefPubMed

48.

Simpson ML, Goldenberg NA, Jacobson LJ, Bombardier CG, Hathaway WE, Manco-Johnson MJ (2011) Simultaneous thrombin and plasmin generation capacities in normal and abnormal states of coagulation and fibrinolysis in children and adults. Thromb Res 127(4):317–323. https://doi.org/10.1016/j.thromres.2010.12.011 CrossRefPubMed

49.

Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S (2003) Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33(1):4–15. https://doi.org/10.1159/000071636 CrossRefPubMed

50.

Kato H, Adachi N, Ohno Y, Iwanaga S, Takada K, Sakakibara S (1980) New fluorogenic peptide substrates for plasmin. J Biochem 88(1):183–190PubMed

Titel: Contradictory to its effects on thrombin, C1-inhibitor reduces plasmin generation in the presence of thrombomodulin
verfasst von: Ivan D. Tarandovskiy
Ali A. Rajabi
Elena Karnaukhova
Paul W. Buehler
Publikationsdatum: 27.04.2019
Verlag: Springer US
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 1/2019
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-019-01869-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Practice patterns of VTE chemoprophylaxis after discharge following hepatic and pancreatic resections for cancer: A survey of hepatopancreatobiliary surgeons

Exosome mediated differentiation of megakaryocytes: a study on TLR mediated effects

Normal D-dimer levels in cancer patients with radiologic evidence of pulmonary embolism

Drug-eluting stents versus bare-metal stents with a single month of dual antiplatelet therapy: a trial sequential analysis

Correction to: Use of oral anticoagulant drugs is associated with carotid intraplaque hemorrhage in atherosclerosis patients: a meta-analysis

Exploring the structural similarity yet functional distinction between coagulation factor XIII-B and complement factor H sushi domains